Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window HONOLULU -- As ...

An initial trial suggests that a new drug, originally developed for use with cancer patients, could improve the survival of patients with acute respiratory distress syndrome (ARDS). The patients in ...

Important factors associated with hospital readmission of children with acute respiratory distress syndrome (ARDS) included an index hospitalization of 14 days or longer and having chronic medical ...

In June 2024, Edesa Biotech, Inc. (NASDAQ:EDSA) announced that EB05 (paridiprubart) was selected by the Biomedical Advanced Research and Development Authority (BARDA) for testing in a U.S.

Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary inflammation and endothelial barrier permeability. Omentin has been shown to benefit obesity-related systemic ...

Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...

Inhaled sedation with sevoflurane in patients with moderate to severe acute respiratory distress syndrome (ARDS) resulted in fewer ventilator-free days at 28 days and lower 90-day survival than ...

From early warnings to smarter ventilators, artificial intelligence is helping clinicians outpace ARDS, offering hope for more lives saved through personalized, data-driven care. Review: Artificial ...

Trimethoprim-sulfamethoxazole (TMP-SMX) treatment may be linked to the onset of severe acute respiratory distress syndrome (ARDS) in adolescents, according to a recent case series published online May ...